pelargonium
sidoid
extract
ep
approv
drug
treatment
acut
bronchiti
germani
postul
mechan
underli
benefici
effect
ep
bronchiti
patient
includ
immunomodulatori
cytoprotect
effect
inhibit
interact
bacteria
host
cell
increas
cilliari
beat
frequenc
respiratori
cell
investig
influenc
ep
replic
panel
respiratori
virus
determin
virusinduc
cytopathogen
effect
viru
titr
reveal
ep
concentr
gml
interf
replic
season
influenza
viru
strain
respiratori
syncyti
viru
human
coronaviru
parainfluenza
viru
coxsacki
viru
affect
replic
highli
pathogen
avian
influenza
viru
adenoviru
rhinoviru
therefor
antivir
effect
may
contribut
benefici
effect
exert
ep
acut
bronchiti
patient
southern
africa
root
pelargonium
sidoid
use
centuri
treatment
differ
aliment
includ
infect
airway
conrad
et
al
brendler
van
wyk
kolodziej
germani
standardis
extract
pelargonium
sidoid
ep
regist
feder
institut
drug
medic
devic
bfarm
indic
acut
bronchiti
conrad
et
al
coupl
randomis
doubleblind
placebocontrol
clinic
trial
support
efficaci
safeti
ep
treatment
acut
bronchiti
adult
children
conrad
et
al
agbabiaka
et
al
matthi
funk
timmer
et
al
kamin
et
al
b
matthi
et
al
postul
mechan
underli
benefici
effect
ep
bronchiti
patient
includ
immunomodulatori
cytoprotect
effect
inhibit
interact
bacteria
host
cell
increas
cilliari
beat
frequenc
respiratori
cell
conrad
et
al
kolodziej
notabl
bacteria
estim
caus
case
uncompl
acut
bronchiti
case
estim
caus
respiratori
virus
gonzal
sand
therefor
effect
ep
replic
respiratori
virus
interest
context
acut
bronchiti
aqueou
extract
pelargonium
sidoid
alreadi
test
antivir
effect
herp
simplex
viru
type
correspond
author
tel
fax
email
address
cinatl
emunifrankfurtd
j
cinatl
jr
schnitzler
et
al
common
virus
caus
recurr
orofaci
genit
lesion
cernik
et
al
extract
inhibit
replic
virus
interfer
viru
surfac
result
viru
inactiv
schnitzler
et
al
investig
effect
ep
viru
replic
broad
panel
respiratori
virus
includ
influenza
viru
respiratori
syncyti
viru
rsv
human
coronaviru
adenoviru
parainfluenza
viru
coxsacki
viru
rhinoviru
ep
provid
phytochemistri
section
depart
preclin
research
dr
willmar
schwabe
pharmaceut
karlsruh
germani
follow
virus
obtain
american
type
cultur
collect
atcc
manassa
va
usa
respiratori
syncyti
viru
rsv
strain
atccno
adenoviru
strain
gb
adeno
atccno
adenoviru
strain
gomen
adeno
atccno
parainfluenza
viru
type
strain
parainfluenza
atccno
human
rhinoviru
strain
rhino
atccno
influenza
viru
strain
anew
receiv
world
cinatl
et
al
coxsacki
cell
cultur
mem
supplement
foetal
calf
serum
fsc
viru
stock
prepar
infect
cell
respect
virus
aliquot
store
c
viru
titr
determin
tissu
cultur
infecti
dose
tcid
ml
microtit
plate
infecti
titr
determin
method
spearman
spearman
mainten
medium
infect
influenza
virus
serumfre
mem
supplement
gml
trypsin
virus
mem
supplement
fc
cytopathogen
effect
cpe
reduct
assay
perform
describ
micha
et
al
confluent
cell
monolay
grown
microtitr
plate
infect
respect
virus
presenc
absenc
ep
follow
multipl
infect
moi
use
influenza
b
coxsacki
rsv
adeno
adeno
parainfluenza
rhino
virusinduc
cpe
record
use
invert
light
microscop
h
influenza
b
coxsacki
coxsacki
h
coxsacki
rhino
h
rsv
parainfluenza
h
adeno
adeno
parainfluenza
post
infect
pi
ep
continu
present
start
h
preincub
period
effect
ep
cell
viabil
investig
noninfect
cell
treat
way
ep
like
virusinfect
cell
cpe
reduct
assay
cell
viabil
determin
bromid
mtt
dye
reduct
assay
describ
micha
et
al
infecti
viru
titr
determin
describ
cell
virus
cell
infect
respect
virus
absenc
presenc
ep
follow
moi
titr
determin
h
post
infect
h
coxsacki
h
coxsacki
moi
h
parainfluenza
h
rsv
h
h
ep
decreas
viabil
investig
cell
type
concentr
gml
moreov
ep
affect
cpe
format
induc
adeno
adeno
rhino
examin
concentr
gml
howev
ep
interf
cpe
format
caus
rsv
parainfluenza
coxsacki
tabl
inhibit
virusinduc
cpe
format
may
consequ
inhibit
viru
replic
cytoprotect
effect
without
influenc
viru
replic
combin
therefor
influenc
ep
investig
rsv
parainfluenza
coxsacki
viru
titr
ep
decreas
titr
suscept
virus
dosedepend
manner
fig
investig
effect
ep
replic
panel
respiratori
virus
ep
inhibit
replic
respiratori
virus
rsv
parainfluenza
coxsacki
magnitud
ep
antivir
effect
differ
sensit
virus
ep
concentr
gml
complet
suppress
replic
season
influenza
viru
strain
rsv
viru
titr
coxsacki
reduc
parainfluenza
decreas
viru
titr
may
suffici
prevent
viral
diseas
especi
preemptiv
set
virus
inhibit
ep
envelop
virus
rsv
parainfluenza
except
coxsacki
nonsensit
virus
nonenvelop
virus
adeno
adeno
rhino
exempt
highli
pathogen
avian
influenza
viru
knipe
howley
therefor
ep
appear
primari
target
envelop
virus
accord
aqueou
extract
pelargonium
sidoid
found
inhibit
replic
envelop
virus
interfer
viru
surfac
result
viru
inactiv
schnitzler
et
al
howev
sinc
ep
inhibit
replic
nonenvelop
coxsacki
mechan
may
also
play
role
vari
sensit
ep
season
influenza
strain
comparison
explain
data
virus
gener
known
less
sensit
antivir
treatment
season
strain
micha
et
al
moreov
influenza
viru
haemagglutinin
protein
bind
sialic
acid
target
cell
surfac
first
step
viral
infect
process
significantli
vari
season
strain
micha
et
al
may
therefor
differ
affect
agent
interact
viru
surfac
conclus
show
pelargonium
sidoid
extract
ep
approv
treatment
acut
bronchiti
interfer
replic
differ
respiratori
virus
includ
season
influenza
viru
strain
rsv
human
coronaviru
parainfluenza
viru
coxsacki
viru
sinc
respiratori
virus
estim
caus
case
acut
bronchiti
gonzal
sand
antivir
effect
may
contribut
benefici
effect
ep
describ
human
acut
bronchiti
patient
conrad
et
al
agbabiaka
et
al
matthi
funk
timmer
et
al
kamin
et
al
b
matthi
et
al
work
financi
support
dr
willmar
schwabe
pharmaceut
karlsruh
germani
